Our group strives to understand the molecular properties allowing antibodies to eliminate a pathogen, merging molecular and cellular biology, biophysics, and computational simulations for structure function studies. This information is used to engineer new antibodies with desired properties.

Projects involve mainly rare and neglected diseases such as Dengue or Zika virus, Prion, Acute Myeloid Leukemias and also SARS-CoVs.

We use a highly multidisciplinary approach, varying from structure determination to cellular experiments, from computational biology to confocal microscopy, from nanoparticles to protein and antibody production and engineering. We are one of the few groups with high impact publications attesting the ability to approach antibody-pathogen interactions both experimentally and computationally. The synergy between computational simulations and classic biophysics, molecular and cellular biology combines the best of both approaches: the low cost and high speed of computers with rigorous and reliable experimental validation. This combined approach is widely considered the future of biomedical sciences.